ArticleMolecular medicine reports2016
miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.Journal of cellular biochemistry · 2018Pooled it
- Prognostic value of miR-26b-5p in prostate cancer and its regulatory effect on tumor progression.World journal of surgical oncology · 2026Article
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Review
- High expression of microRNA-1266 in hepatocellular carcinoma is associated with poor prognosis of patients and biological cell growth.Oncology letters · 2021Article
- MicroRNA-129-5p promotes proliferation and metastasis of hepatocellular carcinoma by regulating the BMP2 gene.Experimental and therapeutic medicine · 2021Article
- Evaluation of the expressed miR-129 and miR-549a in patients with multiple sclerosis.Advanced biomedical research · 2021Article
- [Chloroquine enhances cisplatin-induced apoptosis of nasopharyngeal carcinoma cells by inhibiting autophagy via upregulating miR129].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- miR‑27b‑3p and miR‑607 cooperatively regulate BLM gene expression by directly targeting the 3'‑UTR in PC3 cells.Molecular medicine reports · 2019Article
- Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial-mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2.Cancer cell international · 2019Article
- MiR-129-5p inhibits glioma cell progression in vitro and in vivo by targeting TGIF2.Journal of cellular and molecular medicine · 2018Article
- Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?International journal of molecular sciences · 2017Review
- Lowered levels of microRNA-129 and potential signaling pathways in papillary thyroid carcinoma: a determination of microRNA sequencing in 507 patients and bioinformatics analysis.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are a class of small, well-conserved, non-coding RNAs that are increasingly identified as diagnostic and prognostic biomarkers in a number of cancers. Deregulated miR‑129 is closely associated with tumorigenesis and cancer progression. However, the potential role of miR‑129 in prostate cancer remains largely elusive. The present study investigated the role of miR‑129 as a prognostic biomarker for tumor progression and clinical prognosis in prostate cancer patients. The examined prostate cancer tissues exhibited a significant reduction in miR‑129 expression compared with the normal tissues (P=0.013). The expression levels of miR‑129 were negatively correlated with histological grade (P<0.001), high preoperative prostate‑specific antigen serum levels (P<0.001), pathological stage (P<0.001), high Gleason score (P<0.001), lymph node metastasis (P=0.002), angiolymphatic invasion (P=0.018), and biochemical recurrence (BCR; P=0.001). Use of the Kaplan‑Meier analysis demonstrated that low miR‑129 expression was closely associated with poorer BCR‑free survival. Multivariate survival analysis indicated that miR‑129 expression may be an independent prognostic marker for BCR‑free survival in prostate cancer patients (P<0.001). Overexpression of miR‑129 markedly attenuated prostate cancer cell growth by rescuing cell cycle‑regulated protein expression. The present study suggests that miR‑129 is downregulated in the cancerous tissues of prostate cancer patients, which was associated with poor BCR‑free survival. Thus, it may be considered as a novel independent prognostic biomarker for prostate cancer. In addition, downregulation of miR‑129 may serve a critical role in the proliferation of prostate cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.